Cluster of Excellence –
University of Freiburg

Prof. Dr. Robert Zeiser

Prof. Dr. Robert Zeiser

Hematology and Oncology
University Medical Center Freiburg

+49 761 270 36250

 

The work of my group is focussed on mechanisms that regulate immune responses after allogeneic hematopoietic cell transplantation (allo-HCT). The clinical-translational aspect is that acute graft-versus-host disease is a major barrier for a broader application of allo-HCT in patients with cancer. My group has investigated the role of mTOR signalling for regulatory and conventional T cell function in vivo and described that STAT5 activation is critically involved in regulatory T cell development and maintenance following allo-HCT. Furthermore, we study the role of different GTPases in the process of alloantigen driven T cell responses. We observed that the T cell phenotype and cytokine production is dependent on L-mevalonate metabolites including farnesyl- and geranylgeranylpyrophosphates which mediate attachment of GTPases to the cell membrane. Recently we investigated the role of extracellular ATP as a danger signal activating antigen presenting cells following allo-HCT. Molecular imaging is employed to assess trafficking, survival and proliferation of different immune and cancer cells in vivo.

 

 

10 selected publications

  • Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer.
    Haug S, Schnerch D, Halbach S, Mastroianni J, Dumit VI, Follo M, Hasenburg A, Köhler M, Dierbach H, Herzog S, Proske A, Werner M, Dengjel J, Brummer T, Laßmann S, Wäsch R, Zeiser R (2015).
    Int J Cancer. 136(10):2328-40 
  • Therapeutic activity of multiple common gamma chain cytokine inhibition in acute and chronic GvHD.
    Hechinger AK, Smith BA, Flynn R, Hanke K, McDonald-Hyman C, Taylor PA, Pfeifer D, Hackanson B, Leonhardt F, Prinz G, Dierbach H, Schmitt-Graeff A, Kovarik J, Blazar BR, Zeiser R. (2015)
    Blood 125:570-80
    Highlighted in Pérez-Simón JA. Blood 125: 424-6.2015
  • Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage.
    Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R (2014).
    Nature Medicine  20: 648-54
    Highlighted in Kugelberg E. Nature Reviews Immunology, 2014
  • BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.
    Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R (2014).
    J Clin Invest. 124: 5074-84
    Highlighted in Wu C.J. J Clin Invest. 124:4681-3, 2014
  • MiR-146a regulates the TRAF6/TNF-axis in donor T cells during GvHD.
    Stickel N, Prinz G, Pfeifer D, Hasselblatt P, Schmitt-Graeff A, Follo M, Thimme R, Finke J, Duyster J, Salzer U, Zeiser R (2014).
    Blood 124: 2586-95
  • The Nlrp3-inflammasome regulates acute graft-versus-host disease
    Jankovic D, Ganesan J, Bscheider M, Stickel N, Weber F, Guarda G, Follo M, Pfeifer D, Tardivel A, Ludigs K, Bouazzaoui A, Kerl K, Fischer J, Haas T, Schmitt-Gräff A, Manoharan A, Müller L, Finke J, Martin S, Gorka O, Peschel C, Ruland J, Idzko M, Duyster J, Holler E, French LE, Poeck H*, Contassot E, Zeiser R (2013).
    J Exp Med 210:1899-910       
  • Inflammatory neovascularization during graft-versus-host disease is regulated by ?v integrin and miR-100
    Leonhardt F, Grundmann S, Behe M, Bluhm F, Dumont, RA, Braun F, Melpomeni F, Riesner K, Prinz G, Hechinger AK, Gerlach UV, Dierbach H, Penack O, Schmitt-Gräff A, Finke J, Weber WA, Zeiser R (2013).
    Blood 121:3307-3318
    Highlighted in Komanduri KV et al. Blood 121:3303-4, 2014
  • Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
    Leonhardt F. Zirlik K, Buchner M, Prinz G, Hechinger AK, Gerlach UV, Fisch P, Schmitt-Gräff A, Reichardt W, Zeiser R (2012).
    Leukemia 26: 1617-1629 
  • Graft-versus-host disease is enhanced by extracellular adenosine triphosphate activating P2X7R.
    Wilhelm K, Ganesan J, Müller T, Dürr C, Grimm M, Beilhack A, Krempl CD, Sorichter S, Gerlach UV, Jüttner E, Zerweck A, Gärtner F, Pellegatti P, Di Virgilio F, Ferrari D, Kambham N, Fisch P, Finke J, Idzko M, Zeiser R (2010)
    Nature Medicine  12: 1434-1438
  • CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.
    Dürr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R, Krüger S, Gerbitz A, Negrin RS, Finke J, Zeiser R (2010).
    Cancer Research 70: 10170-10181